BidaskClub cut shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) from a hold rating to a sell rating in a research note issued to investors on Tuesday.

Several other analysts also recently commented on the stock. Jefferies Group LLC reissued a buy rating and issued a $30.00 target price on shares of Atara Biotherapeutics in a research report on Thursday, June 22nd. Zacks Investment Research downgraded shares of Atara Biotherapeutics from a hold rating to a sell rating in a research report on Tuesday, May 9th. William Blair reissued an outperform rating on shares of Atara Biotherapeutics in a research report on Monday, June 26th. ValuEngine downgraded shares of Atara Biotherapeutics from a sell rating to a strong sell rating in a research report on Tuesday, August 1st. Finally, Canaccord Genuity set a $47.00 target price on shares of Atara Biotherapeutics and gave the stock a buy rating in a research report on Monday, August 7th. Four research analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus target price of $23.60.

Shares of Atara Biotherapeutics (ATRA) opened at 13.85 on Tuesday. Atara Biotherapeutics has a 12 month low of $11.80 and a 12 month high of $23.00. The firm has a 50-day moving average price of $14.82 and a 200-day moving average price of $15.90. The stock’s market cap is $423.24 million.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.94) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by $0.05. Equities analysts expect that Atara Biotherapeutics will post ($3.89) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Atara Biotherapeutics, Inc. (ATRA) Rating Lowered to Sell at BidaskClub” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/08/26/atara-biotherapeutics-inc-atra-rating-lowered-to-sell-at-bidaskclub.html.

In related news, EVP Christopher Haqq sold 7,604 shares of the company’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $14.75, for a total transaction of $112,159.00. Following the completion of the sale, the executive vice president now directly owns 362,909 shares of the company’s stock, valued at approximately $5,352,907.75. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Isaac E. Ciechanover sold 3,450 shares of the company’s stock in a transaction on Tuesday, May 30th. The stock was sold at an average price of $13.44, for a total transaction of $46,368.00. Following the sale, the chief executive officer now directly owns 731,859 shares of the company’s stock, valued at $9,836,184.96. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 56,459 shares of company stock valued at $811,787. 16.10% of the stock is owned by insiders.

Several hedge funds have recently bought and sold shares of the company. Redmile Group LLC increased its stake in Atara Biotherapeutics by 2.4% in the first quarter. Redmile Group LLC now owns 2,734,118 shares of the biotechnology company’s stock valued at $56,186,000 after buying an additional 63,176 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Atara Biotherapeutics by 617.9% in the first quarter. Goldman Sachs Group Inc. now owns 201,214 shares of the biotechnology company’s stock valued at $4,135,000 after buying an additional 173,184 shares in the last quarter. American International Group Inc. increased its stake in Atara Biotherapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 948 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Atara Biotherapeutics during the first quarter valued at about $132,000. Finally, Vident Investment Advisory LLC increased its stake in Atara Biotherapeutics by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 55,665 shares of the biotechnology company’s stock valued at $1,144,000 after buying an additional 9,276 shares in the last quarter. 78.21% of the stock is owned by institutional investors and hedge funds.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.